deferoxamine has been researched along with Hyperparathyroidism, Secondary in 10 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Hyperparathyroidism, Secondary: Abnormally elevated PARATHYROID HORMONE secretion as a response to HYPOCALCEMIA. It is caused by chronic KIDNEY FAILURE or other abnormalities in the controls of bone and mineral metabolism, leading to various BONE DISEASES, such as RENAL OSTEODYSTROPHY.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Twenty-four patients, 15 with dialysis osteomalacia and nine with clinically apparent secondary hyperparathyroidism, had serum aluminum levels measured before and after a standard infusion of a chelating agent, deferoxamine (DFO)." | 3.67 | Do serum aluminum levels reflect underlying skeletal aluminum accumulation and bone histology before or after chelation by deferoxamine? ( Brown, P; Cordy, PE; Hodsman, AB; Hood, SA, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (60.00) | 18.7374 |
| 1990's | 3 (30.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yamamoto, I | 1 |
| Kawamura, Y | 1 |
| Hirano, K | 1 |
| Hayakawa, H | 1 |
| Shigematu, T | 1 |
| Panico, F | 1 |
| Salvati, A | 1 |
| Scoppa, F | 1 |
| Testa, GF | 1 |
| Capobianco, A | 1 |
| Pacia, S | 1 |
| Lauriello, F | 1 |
| Aquino, A | 1 |
| Tedesco, V | 1 |
| Taccone, W | 1 |
| Geffriaud, C | 1 |
| Allinne, E | 1 |
| Page, B | 1 |
| Zingraff, J | 2 |
| Jucquel, JP | 1 |
| Bardin, T | 1 |
| Drüeke, TB | 1 |
| Fournier, A | 1 |
| Morinière, P | 1 |
| Ben Hamida, F | 1 |
| el Esjer, N | 1 |
| Shenovda, M | 1 |
| Ghazali, A | 1 |
| Bouzernidj, M | 1 |
| Achard, JM | 1 |
| Westeel, PF | 1 |
| Ureña, P | 1 |
| Basile, C | 1 |
| Grateau, G | 1 |
| Lacour, B | 1 |
| Vassault, A | 1 |
| Bourdeau, A | 1 |
| Bourdon, R | 1 |
| Dubost, C | 1 |
| Drüeke, T | 1 |
| Boyce, BF | 1 |
| Mocan, MZ | 1 |
| Byars, J | 1 |
| Junor, BJ | 1 |
| Coburn, JW | 1 |
| Norris, KC | 1 |
| Sherrard, DJ | 1 |
| Bia, M | 1 |
| Llach, F | 1 |
| Alfrey, AC | 1 |
| Slatopolsky, E | 1 |
| Iwamoto, N | 1 |
| Ono, T | 1 |
| Yamazaki, S | 1 |
| Fukuda, T | 1 |
| Kondo, M | 1 |
| Yamamoto, N | 1 |
| Hiratake, Y | 1 |
| Masugi, Y | 1 |
| Kubo, Y | 1 |
| Hino, M | 1 |
| Botella, J | 1 |
| Gallego, JL | 1 |
| Fernandez-Fernandez, J | 1 |
| Sanz-Guajardo, D | 1 |
| de Miguel, A | 1 |
| Ramos, J | 1 |
| Franco, P | 1 |
| Enriques, R | 1 |
| Sanz-Moreno, C | 1 |
| Hodsman, AB | 1 |
| Hood, SA | 1 |
| Brown, P | 1 |
| Cordy, PE | 1 |
2 reviews available for deferoxamine and Hyperparathyroidism, Secondary
| Article | Year |
|---|---|
[Therapy for ROD and measurement of the bone mass].
Topics: Absorptiometry, Photon; Bone Density; Calcitriol; Calcium; Chronic Kidney Disease-Mineral and Bone D | 2004 |
Use of alkaline calcium salts as phosphate binder in uremic patients.
Topics: Aluminum; Calcinosis; Calcitriol; Calcium; Deferoxamine; Humans; Hyperparathyroidism, Secondary; Pho | 1992 |
8 other studies available for deferoxamine and Hyperparathyroidism, Secondary
| Article | Year |
|---|---|
[Interaction between active metabolites of vitamin D3 and blood aluminum in chronic uremic patients on dialysis].
Topics: Adolescent; Adult; Aged; Aluminum; Aluminum Hydroxide; Calcitriol; Chronic Disease; Deferoxamine; Dr | 1993 |
Decrease of tumor-like calcification in uremia despite aggravation of secondary hyperparathyroidism: a case report.
Topics: Aluminum; Calcinosis; Chelation Therapy; Connective Tissue Diseases; Deferoxamine; Female; Humans; H | 1992 |
Short-term effects of parathyroidectomy on plasma biochemistry in chronic uremia.
Topics: Alkaline Phosphatase; Aluminum; Bone and Bones; Calcifediol; Calcium; Chronic Disease; Cohort Studie | 1989 |
Treatment and histological healing of aluminum-related osteomalacia.
Topics: Adult; Aluminum; Calcium; Deferoxamine; Female; Hemodialysis Solutions; Humans; Hyperparathyroidism, | 1988 |
Toxic effects of aluminum in end-stage renal disease: discussion of a case.
Topics: Aluminum; Bone Diseases, Metabolic; Brain Diseases; Deferoxamine; Female; Hemodialysis, Home; Humans | 1988 |
Clinical features of aluminum-associated bone disease in long-term hemodialysis patients.
Topics: Adult; Aged; Aluminum; Bone and Bones; Chronic Kidney Disease-Mineral and Bone Disorder; Deferoxamin | 1986 |
The bone scan in patients with aluminium-associated bone disease.
Topics: Aluminum; Deferoxamine; Humans; Hyperparathyroidism, Secondary; Osteomalacia; Radionuclide Imaging; | 1985 |
Do serum aluminum levels reflect underlying skeletal aluminum accumulation and bone histology before or after chelation by deferoxamine?
Topics: Adult; Aluminum; Biopsy; Bone and Bones; Deferoxamine; Dementia; Humans; Hyperparathyroidism, Second | 1985 |